Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jun 21, 2015; 21(23): 7281-7288
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281
Table 1 Baseline patient characteristics
Characteristicn (%)1
Total recruitment205 (100)
ITT population197 (96.1)
Age (yr)
Median (range)63 (34-80)
mean ± SD62.3 ± 9.9
Gender
Males111 (56.4)
Females86 (43.6)
ECOG-PS
0159 (80.7)
138 (19.3)
> 10 (0)
Site of primary tumor
Colon (any region)141 (71.6)
Rectum46 (23.4)
Rectum + colon (any region)8 (4.1)
Unknown2 (1.0)
Prior treatments (adjuvant or neo-adjuvant)
Chemotherapy49 (24.9)
Radiotherapy21 (10.7)
None148 (75.1)
N of metastases for each patient
1105 (53.3)
272 (36.5)
> 320 (10.2)
Site of metastases
Liver150 (76.1)
Lung70 (35.5)
Lymph nodes27 (13.7)
Peritoneum14 (7.1)
Other98 (48)
Stage at first diagnosis
Local regional75 (38.1)
Metastatic122 (61.9)
KRAS and BRAF mutation status (34 evaluated)
Wild Type (KRAS/BRAF)18 (52.9)
Mutated KRAS13 (38.2)
Mutated BRAF2 (5.9)
Mutated KRAS and BRAF1 (2.9)
Table 2 Overall response rate of the intention-to-treat population
n (%)1
CR (best overall response)10 (5.1)
PR87 (44.2)
SD55 (27.9)
CB (CR + PR + SD)152 (77.1)
PD13 (6.6)
No tumor assessment32 (16.2)
Table 3 Summary of R0 resection rates
Reason for surgeryResidual diseasen (%)1
Curative
No (radical surgery)26 (55.8)
Yes7 (13.5)
Unknown2 (3.9)
Not applicable4 (7.7)
Palliative
No (radical surgery)2 (3.9)
Yes4 (7.7)
Unknown2 (3.9)
Not applicable1 (1.9)
Biopsy
Yes1 (1.9)
Not applicable1 (1.9)
Unknown
Unknown1 (1.9)
Not applicable2 (3.9)
Other
Yes1 (1.9)
Not applicable2 (3.9)